Bcl-2 family-regulated apoptosis in health and disease

Cell Health and Cytoskeleton

Volumn 2, Issue 1, 2010, Pages 9-22

  Dewson, Grant ^a   Kluck, Ruth M ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Apoptosis; Bcl 2; Cancer; Cytochrome c; Mitochondria

Indexed keywords

EID: 78449249926     PISSN: None     EISSN: 11791330     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene. 1987;2(1):3-7.
2. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
3. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
4. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science. 2003;302:1036-1038.
5. Puthalakath H, Huang DCS, O'Reilly LA, King SM, Strasser A. The pro-apoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3:287-296.
6. Puthalakath H, Villunger A, O'Reilly LA, et al. Bmf: A pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001;293:1829-1832.
7. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, Diamandis EP. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics. 2001;72(2):217-221.
8. Coultas L, Pellegrini M, Visvader JE, et al. Bfk: A novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death Differ. 2003;10(2):185-192.
9. Guo B, Godzik A, Reed JC. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem. 2001;276(4):2780-2785.
10. Stegh AH, Kim H, Bachoo RM, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 2007;21(1):98-111.
11. Kataoka T, Holler N, Micheau O, et al. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem. 2001;276(22):19548-19554.
12. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer S. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;74:241-251.
13. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993;75:229-240.
14. Gardner A, Xu FH, Fady C, Sarafian T, Tu Y, Lichtenstein A. Evidence against the hypothesis that BCL-2 inhibits apoptosis through an anti-oxidant effect. Cell Death Differ. 1997;4:487-496.
15. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434(7033):652-658.
16. Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell. 1994;79(2):353-364.
17. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria - a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132-1136.
18. Yang J, Liu XS, Bhalla K, et al. Prevention of apoptosis by Bcl-2 - release of cytochrome c from mitochondria blocked. Science. 1997;275(5303): 1129-1132.
19. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell. 1996;86:147-157.
20. Verhagen AM, Ekert PG, Pakusch M, et al. Identif ication of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing inhibitor of apoptosis (IAP) proteins. Cell. 2000;102(1):43-53.
21. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33-42.
22. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17(6):1675-1687.
23. McKenzie MD, Carrington EM, Kaufmann T, et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes. 2008;57(5):1284-1292.
24. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400(6747):886-891.
25. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997;139(5):1281-1292.
26. Wilson-Annan J, O'Reilly LA, Crawford SA, et al. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol. 2003;162(5):877-888.
27. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis. Proc Natl Acad Sci U S A. 1997;94:3668-3672.
28. He H, Lam M, McCormick TS, Distelhorst CW. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J Cell Biol. 1997;138(6):1219-1228.
29. Zong WX, Li C, Hatzuvassiliou G, et al. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol. 2003;162(1):59-69.
30. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000;14(16):2060-2071.
31. Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science. 2003;300(5616):135-139.
32. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol. 2001;153(6):1265-1276.
33. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol. 1999;144(5):903-914.
34. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J. 1999;18(9):2330-2341.
35. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7(12):1166-1173.
36. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18(4):157-164.
37. Dewson G, Kluck RM. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci. 2009;122 (Pt 16):2801-2808.
38. Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183-192.
39. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292(5517):727-730.
40. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315(5813):856-859.
41. Willis SN, Chen L, Dewson G, et al. Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294-1305.
42. Ruffolo SC, Shore GC. BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization. J Biol Chem. 2003;278(27):25039-25045.
43. Leber B, Lin J, Andrews DW. Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis. 2007;12(5):897-911.
44. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 1996;381:335-341.
45. Petros AM, Medek A, Nettesheim DG, et al. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A. 2001;98(6): 3012-3017.
46. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DCS, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem. 2005;280(6):4738-4744.
47. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DCS, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J. 2003;22(7):1497-1507.
48. Smits C, Czabotar PE, Hinds MG, Day CL. Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure. 2008;16(5):818-829.
49. Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. PNAS. 2007;104(15):6217-6222.
50. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science. 1997;275(5302):983-986.
51. Petros AM, Nettseheim DG, Wang Y, et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 2000;9:2528-2534.
52. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: Coregulation of dimmer formation and intracellular localization. Cell. 2000;103:645-654.
53. Moldoveanu T, Liu Q, Tocilj A, Watson MH, Shore G, Gehring K. The x-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell. 2006;24(5):677-688.
54. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644(2-3):83-94.
55. Hinds MG, Smits C, Fredericks-Short R, et al. Bim, Bad and Bmf: Intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 2007;14:128-136.
56. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplif ier of apoptotic signaling. Cell. 1999;96(5):615-624.
57. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: A structural basis for apoptotic agonists and antagonists. Cell. 1999;96(5): 625-634.
58. Yao Y, Bobkov AA, Plesniak LA, Marassi FM. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. Biochemistry. 2009;48(36):8704-8711.
59. Chen L, Willis SN, Wei A, et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393-403.
60. Dewson G, Kratina T, Sim HW, et al. To trigger apoptosis Bak exposes its BH3 domain and homo-dimerizes via BH3: Groove interactions. Mol Cell. 2008;30(3):369-380.
61. Bleicken S, Classen M, Padmavathi PV, et al. Molecular details of Bax activation, oligomerization and membrane insertion. J Biol Chem. 2010;285(9):6636-6647.
62. Gavathiotis E, Suzuki M, Davis ML, et al. BAX activation is initiated at a novel interaction site. Nature. 2008;455(7216):1076-1081.
63. Kim H, Tu HC, Ren D, et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009;36(3):487-499.
64. Griffiths GJ, Corfe BM, Savory P, et al. Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene. 2001;20(52):7668-7676.
65. Annis MG, Soucie EL, Dlugosz PJ, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 2005;24(12):2096-2103.
66. Kim PK, Annis MG, Dlugosz PJ, Leber B, Andrews DW. During apoptosis bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondria. Mol Cell. 2004;14:523-529.
67. Antignani A, Youle RJ. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr Opin Cell Biol. 2006;18(6):685-689.
68. Dlugosz PJ, Billen LP, Annis MG, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 2006;25(11):2287-2296.
69. Gong XM, Choi J, Franzin CM, Zhai D, Reed JC, Marassi FM. Conformation of membrane-associated proapoptotic tBid. J Biol Chem. 2004;279(28):28954-28960.
70. Aisenbrey C, Sudheendra US, Ridley H, et al. Helix orientations in membrane-associated Bcl-X(L) determined by 15N-solid-state NMR spectroscopy. Eur Biophys J. 2007;37(1):71-80.
71. Losonczi JA, Olejniczak ET, Betz SF, Harlan JE, Mack J, Fesik SW. NMR studies of the anti-apoptotic protein Bcl-xL in micelles. Biochemistry. 2000;39(36):11024-11033.
72. Franzin CM, Choi J, Zhai D, Reed JC, Marassi FM. Structural studies of apoptosis and ion transport regulatory proteins in membranes. Magn Reson Chem. 2004;42(2):172-179.
73. Kvansakul M, Yang H, Fairlie WD, et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ. 2008;15(10):1564-1571.
74. Douglas AE, Corbett KD, Berger JM, McFadden G, Handel TM. Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci. 2007;16(4):695-703.
75. Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET. Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol. 2003;332(5):1123-1130.
76. Postigo A, Cross JR, Downward J, Way M. Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Differ. 2006;13(10):1651-1662.
77. Wang G, Barrett JW, Nazarian SH, et al. Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol. 2004;78(13):7097-111.
78. Graham SC, Bahar MW, Cooray S, et al. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog. 2008;4(8):e1000128.
79. Motoyama N, Wang FP, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science. 1995;267:1506-1510.
80. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671-676.
81. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339-352.
82. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 1998;94(3):325-337.
83. Yoshida H, Kong YY, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 1998;94(6): 739-750.
84. Hao Z, Duncan GS, Chang CC, et al. Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell. 2005;121(4): 579-591.
85. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell. 2000;6(6):1389-1399.
86. Knudson CM, Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 1995;270:96-99.
87. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286:1735-1738.
88. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
89. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1): 57-70.
90. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348:331-333.
91. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76(7):935-938.
92. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res. 1998;4(4):1071-1074.
93. Jansson A, Sun XF. Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002;20(3): 811-816.
94. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126(6):1366-1371.
95. Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15(4): 1126-1132.
96. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681.
97. Lee EF, Czabotar PE, Smith BJ, et al. Crystal structure of ABT-737 complexed with Bcl-x(L): Implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 2007;14(9):1711-1713.
98. Certo M, del Gaizo Moore G, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351-365.
99. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374-2380.
100. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 2007;110(6):2057-2066.
101. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121.
102. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9): 3421-3428.
103. Michaelidis TM, Sendtner M, Cooper JD, et al. Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron. 1996;17:75-89.
104. Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron. 1994;13:1017-1030.
105. Perier C, Bove J, Wu DC, et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A. 2007; 104(19):8161-8166.
106. Armstrong JS. Mitochondrial medicine: Pharmacological targeting of mitochondria in disease. Br J Pharmacol. 2007;151(8):1154-1165.
107. Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res. 2006;10(3-4):181-192.
108. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol. 2007;292(1):C45-C51.
109. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation. 1997;96(5):1580-1585.
110. Imahashi K, Schneider MD, Steenbergen C, Murphy E. Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res. 2004;95(7):734-741.
111. Maulik N, Engelman RM, Rousou JA, Flack JE, 3rd, Deaton D, Das DK. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation. 1999;100(19 Suppl): II369-II375.
112. Hochhauser E, Cheporko Y, Yasovich N, et al. Bax deficiency reduces infarct size and improves long-term function after myocardial infarction. Cell Biochem Biophys. 2007;47(1):11-20.
113. Webster KA. Programmed death as a therapeutic target to reduce myocardial infarction. Trends Pharmacol Sci. 2007;28(9):492-499.
114. Dewson G, Wardlaw AM, Walsh GM. Human eosinophils: Apoptosis versus survival in the mediation of inflammation. Apoptosis. 1996;1:111-118.
115. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol. 2000;106(1):77-83.
116. Tumes DJ, Wong AC, Sewell WA, McColl SR, Connolly A, Dent LA. Differential rates of apoptosis and recruitment limit eosinophil accumulation in the lungs of asthma-resistant CBA/Ca mice. Mol Immunol. 2008;45(13):3609-3617.
117. Dewson G, Walsh GM, Wardlaw AJ. Expression of Bcl-2 and its homologues in human eosinophils. Modulation by interleukin-5. Am J Respir Cell Mol Biol. 1999;20(4):720-728.
118. Dewson G, Cohen GM, Wardlaw AJ. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils. Blood. 2001;98(7): 2239-2247.
119. Jang AS, Choi IS, Lee S, Seo JP, Yang SW, Park CS. Bcl-2 expression in sputum eosinophils in patients with acute asthma. Thorax. 2000;55(5):370-374.
120. El-Gamal Y, Heshmat N, Mahran M, El-Gabbas Z. Expression of the apoptosis inhibitor Bcl-2 in sputum eosinophils from children with acute asthma. Clin Exp Allergy. 2004;34(11):1701-1706.
121. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2): 66-70.
122. Duffin R, Leitch AE, Sheldrake TA, et al. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett. 2009;583(15):2540-2546.
123. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101(4):890-898.
124. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-110.
125. Grunnet LG, Aikin R, Tonnesen MF, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009;58(8):1807-1815.
126. Tran VV, Chen G, Newgard CB, Hohmeier HE. Discrete and complementary mechanisms of protection of beta-cells against cytokine-induced and oxidative damage achieved by bcl-2 overexpression and a cytokine selection strategy. Diabetes. 2003;52(6): 1423-1432.
127. McKenzie MD, Jamieson E, Jansen ES, et al. Glucose induces pancreatic islet cell apoptosis that requires the BH3-only proteins Bim and Puma and multi-BH domain protein Bax. Diabetes. 2010;59(3): 644-652.
128. Perlman H, Georganas C, Pagliari LJ, Koch AE, Haines K 3rd, Pope RM. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol. 2000;164(10):5227-5235.
129. Busteed S, Bennett MW, Molloy C, et al. Bcl-x(L) expression in vivo in rheumatoid synovium. Clin Rheumatol. 2006;25(6):789-793.
130. Liu H, Eksarko P, Temkin V, et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2005;175(12):8337-8345.
131. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol. 2003;3(3):317-322.
132. Hutcheson J, Perlman H. BH3-only proteins in rheumatoid arthritis: Potential targets for therapeutic intervention. Oncogene. 2008;27 Suppl 1:S168-S175.
133. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952-6963.
134. Tinsley KW, Grayson MH, Swanson PE, et al. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol. 2003;171(2):909-914.
135. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol. 1999;162:4148-4156.
136. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6(11):813-822.
137. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets. 2007;8(4):493-500.
138. Huang DCS, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998;17(4):1029-1039.